Immunic, Inc.

NasdaqCM:IMUX Stock Report

Market Cap: US$158.0m

Immunic Management

Management criteria checks 3/4

Immunic's CEO is Daniel Vitt, appointed in Apr 2019, has a tenure of 7.08 years. total yearly compensation is $2.31M, comprised of 27.1% salary and 72.9% bonuses, including company stock and options. directly owns 0.29% of the company’s shares, worth $454.58K. The average tenure of the management team and the board of directors is 4.8 years and 5.5 years respectively.

Key information

Daniel Vitt

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage27.05%
CEO tenure7.1yrs
CEO ownership0.3%
Management average tenure4.8yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

Analysis Article • Oct 17

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jun 09

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Summary Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results. We reiterate our Strong Buy rating, viewing the stock dip as a buying opportunity for investors with high-risk tolerance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 28

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Summary Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammatory benefits, positioning it as a potential next-gen oral MS treatment. Financial risks include ongoing cash burn and potential dilution, but management has a track record of successful fund-raising to support R&D efforts. Read the full article on Seeking Alpha
Analysis Article • Oct 25

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 22

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.
Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.
Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2  $88.1 million.
Analysis Article • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 13

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Dec 24

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Daniel Vitt's remuneration changed compared to Immunic's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$2mUS$625k

-US$97m

Sep 30 2025n/an/a

-US$103m

Jun 30 2025n/an/a

-US$102m

Mar 31 2025n/an/a

-US$96m

Dec 31 2024US$3mUS$610k

-US$101m

Sep 30 2024n/an/a

-US$97m

Jun 30 2024n/an/a

-US$95m

Mar 31 2024n/an/a

-US$98m

Dec 31 2023US$1mUS$585k

-US$94m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$125m

Dec 31 2022US$3mUS$520k

-US$120m

Sep 30 2022n/an/a

-US$85m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$79m

Dec 31 2021US$2mUS$399k

-US$93m

Sep 30 2021n/an/a

-US$83m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$1mUS$381k

-US$44m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$39m

Dec 31 2019US$2mUS$202k

-US$35m

Compensation vs Market: Daniel's total compensation ($USD2.31M) is above average for companies of similar size in the US market ($USD1.73M).

Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.

CEO

Daniel Vitt (57 yo)

7.1yrs
Tenure
US$2,311,272
Compensation

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic, Inc. since April 2019 and also served as its President until July 12, 2024. He is also managing director of Immunic Research GmbH in Ha...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 454.6k
Jason Tardio
COO & President1.8yrsUS$1.21m0.0092%
$ 14.5k
Glenn Whaley
Chief Financial Officer6.1yrsUS$1.07m0.070%
$ 110.8k
Hella Kohlhof
Chief Scientific Officer9.3yrsno datano data
Jessica Breu
Head of Investor Relations & Communicationsno datano datano data
Inderpal Singh
General Counsel4.9yrsno datano data
Patrick Walsh
Chief Business Officer4.6yrsno datano data
Werner Gladdines
Chief Development Officer1.8yrsno datano data
Michael A. Panzara
Chief Medical Officerless than a yearno datano data
4.8yrs
Average Tenure
54yo
Average Age

Experienced Management: IMUX's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 454.6k
Barclay Phillips
Lead Independent Director6.5yrsUS$171.98k0.11%
$ 180.9k
Tamar Howson
Independent Director6.6yrsUS$149.82k0.11%
$ 180.9k
Jorg Neermann
Independent Director7.1yrsUS$156.98k0.15%
$ 232.0k
Paul Utz
Member of Scientific Medical Advisory Board5.5yrsno datano data
Duane Nash
Director7.3yrsUS$982.95k0.026%
$ 41.8k
Bruce Sands
Member of Scientific Medical Advisory Board5.5yrsno datano data
Fred Lublin
Member of Scientific Medical Advisory Board5.5yrsno datano data
Richard Rudick
Independent Director3.1yrsUS$149.48k0.17%
$ 267.2k
Jon Congleton
Independent Directorless than a yearno datano data
Simona Skerjanec
Independent Interim Chairperson1.8yrsUS$149.14kno data
Thorvald Nagel
Independent Directorless than a yearno datano data
5.5yrs
Average Tenure
60yo
Average Age

Experienced Board: IMUX's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 10:34
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunic, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George FarmerBMO Capital Markets Equity Research
William WoodB. Riley Securities, Inc.
Tyler BussianBrookline Capital Markets